Skip to content
Clinical Trials – home
Vaestra Goetalandsregionen
Sponsor

Vaestra Goetalandsregionen

Sweden Regionens Hus, 462 80 Vänersborg, Sweden

About the sponsor

Research activity spans pancreatic cancer, glioblastoma, non-small cell lung cancer, multiple myeloma, breast cancer, and a broad range of melanoma subtypes, including uveal melanoma with liver metastases and in-transit metastasis. The portfolio also includes acute myeloid leukemia in both adult and pediatric settings, along with pediatric cancer and biomarker-oriented targeted cancer treatment.

  • Pancreatic adenocarcinoma
  • Melanoma and uveal melanoma
  • Glioblastoma
  • Acute myeloid leukemia
  • Multiple myeloma

Additional interest extends to somatostatin receptor positive tumours, metastatic disease, and surgical oncology contexts linked to hepatic resection and liver metastases.

About Specializations

Vaestra Goetalandsregionen runs clinical trials in conditions such as Pancreatic carcinoma, Acute myeloid leukaemia, Acute myocardial infarction, Coronary artery disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

41 clinical trials

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Vaestra Goetalandsregionen
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Vaestra Goetalandsregionen
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Vaestra Goetalandsregionen

Measles

Recruiting
Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · Healthy volunteers
  • Substances:MEASLES VIRUS EDMONSTON-SCHWARZ STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS
  • Sponsor:Vaestra Goetalandsregionen
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Digitoxin
  • Sponsor:Vaestra Goetalandsregionen
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Human Papillomavirus Type 11 L1 Protein
  • Sponsor:Vaestra Goetalandsregionen
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Hypochlorite
  • Sponsor:University Of Gothenburg
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Vaestra Goetalandsregionen
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dexmedetomidine
  • Sponsor:Vaestra Goetalandsregionen
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Vaestra Goetalandsregionen
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Vaestra Goetalandsregionen

Glioblastoma

Recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Region Oestergoetland

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).